<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01280045</url>
  </required_header>
  <id_info>
    <org_study_id>FMRPUSP-UROGIN-001</org_study_id>
    <nct_id>NCT01280045</nct_id>
  </id_info>
  <brief_title>Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy</brief_title>
  <official_title>Influence of the Aromatase Inhibitor Anastrozole and GnRH Analog Goserelin Acetate as Preoperative Treatment of Vaginal Surgical Treatment of Uterine Leiomyoma: Analysis of Intra and Immediate/Late Postoperative Patterns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to assess if use of aromatase inhibitors could decrease volume of
      uterine leiomyoma and cause same percentage of adverse effects during its use compared to
      GnRH analogs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uterine leiomyoma is the most prevalent benign gynecologic tumor in women. Standard treatment
      is surgical (hysterectomy or myomectomy), and depends of many variables. If these tumors are
      large, preoperative assessment with clinical treatment may be useful in order to decrease its
      volume, improve hematologic patterns and modify surgical approach (vaginal or abdominal). It
      is well know that GnRH analogs can cause these goals; however, aromatase inhibitors are new
      promising drugs which are being used for reducing uterine leiomyoma's volume and few
      observational studies have shown this fact. The investigators are aiming to compare both
      treatments in a randomized controlled trial and see if it both treatments are similar or not
      in decreasing uterine leiomyoma's volume, influencing operative time, blood loss during
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Operative Time</measure>
    <time_frame>3 Months After Clinical Treatment, During Surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uterine Leiomyoma Volume</measure>
    <time_frame>3 Months After Treatment, During Surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>UTERINE LEIOMYOMA</condition>
  <arm_group>
    <arm_group_label>AROMATASE INHIBITOR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GNRH ANALOG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VAGINAL HYSTERECTOMY</intervention_name>
    <description>GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS</description>
    <arm_group_label>AROMATASE INHIBITOR</arm_group_label>
    <arm_group_label>GNRH ANALOG</arm_group_label>
    <other_name>None declared</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  WOMEN OVER 40 YEARS, UTERINE VOLUME HIGHER THAN 300 ML, MINIMAL ANATOMIC CONDITIONS
             FOR VAGINAL SURGERY

        Exclusion Criteria:

          -  ACTIVE GYNECOLOGIC MALIGNANCY
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco J Candido dos Reis, MD</last_name>
    <role>Study Chair</role>
    <affiliation>FMRP-USP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LUIZ GUSTAVO O BRITO, MD</last_name>
    <phone>+551632356626</phone>
    <email>lbrito@usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Medicine of Ribeirao Preto - Sao Paulo University</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>Sao Paulo</state>
        <zip>14049900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FRANCISCO J CANDIDO DOS REIS, MD, PHD</last_name>
      <phone>+551636021000</phone>
      <phone_ext>2585</phone_ext>
      <email>fjcreis@fmrp.usp.br</email>
    </contact>
    <investigator>
      <last_name>LUIZ GUSTAVO O BRITO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>PEDRO S MAGNANI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>HEITOR LEANDRO P RODRIGUES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MARIA ANGELA C CARVALHO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>MAURICIO M SABINO-DE-FREITAS, MD, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Parsanezhad ME, Azmoon M, Alborzi S, Rajaeefard A, Zarei A, Kazerooni T, Frank V, Schmidt EH. A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010 Jan;93(1):192-8. doi: 10.1016/j.fertnstert.2008.09.064. Epub 2009 Jan 9.</citation>
    <PMID>19135657</PMID>
  </results_reference>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2011</study_first_submitted>
  <study_first_submitted_qc>January 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2011</study_first_posted>
  <last_update_submitted>May 29, 2012</last_update_submitted>
  <last_update_submitted_qc>May 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>LUIZ GUSTAVO OLIVEIRA BRITO</investigator_full_name>
    <investigator_title>Assistant Physician, MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyoma</mesh_term>
    <mesh_term>Myofibroma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

